KCM
AXDX

Kornitzer Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

Kornitzer Capital Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-44,261
Closed -$10.1M – 462
2018
Q1 		$10.1M Buy
44,261
+311
+0.7% +$81.7K 0.17% 169
2017
Q4 		$11.5M Sell
43,950
-9,072
-17% -$2.13M 0.2% 155
2017
Q3 		$11.9M Buy
53,022
+14,406
+37% +$3.54M 0.21% 149
2017
Q2 		$10.6M Buy
38,616
+15,513
+67% +$4.2M 0.18% 168
2017
Q1 		$5.59M Buy
+23,103
New +$5.28M 0.1% 247

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Kornitzer Capital Management's AXDX Position: Q2 2018 in Review

Kornitzer Capital Management sold out of Accelerate Diagnostics (AXDX) in Q2 2018, closing a stake of 44,261 shares — an estimated $10.1M sold.

Kornitzer Capital Management first reported a position in AXDX in Q1 2017 and held it in 5 quarters. The position peaked at $11.9M in Q3 2017. 116 funds tracked by Wall St. Rank hold AXDX as of Q2 2018.

  • Kornitzer Capital Management reported no remaining Accelerate Diagnostics position as of Q2 2018 after selling out during the quarter.
  • Kornitzer Capital Management sold 44,261 Accelerate Diagnostics shares in Q2 2018, an estimated $10.1M.
  • Kornitzer Capital Management first reported a position in Accelerate Diagnostics in Q1 2017 and held it in 5 quarters.
  • Kornitzer Capital Management's Accelerate Diagnostics position peaked at $11.9M in Q3 2017.
  • 116 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2018.

Based on Kornitzer Capital Management's 13F filing for Q2 2018, filed 2 Aug 2018.